# Adient plc (ADNT) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ADNT/thesis · /stocks/ADNT/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
ticker: ADNT
company: Adient plc
date: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Sweep: ADNT (Adient plc)

#### 1. Income Statement Quality

##### Revenue Recognition
Adient recognizes revenue consistent with ASC 606 on a per-unit / per-program basis as seats are delivered to OEM assembly lines. Revenue is point-in-time (delivery), not over-time. Quality: **HIGH** — no concern with timing manipulation; physical delivery is verifiable. [S1]

##### Adjusted EBITDA vs. GAAP
Adient's management-defined "Adj. EBITDA" is the primary reported profitability metric. Key adjustments include:

| Adjustment | FY2025 | FY2024 | Nature |
|------------|--------|--------|--------|
| Restructuring / exceptional | ~$180M | ~$159M | Cash, recurring in nature |
| Goodwill impairment | ~$333M | ~$0M | Non-cash, EMEA segment |
| KEIPER impairment/losses | ~$30M | ~$60M | JV-related non-cash |
| Equity income adj. | Various | Various | JV attribution |

**FLAG:** The restructuring charges (~$159-180M in both FY2024 and FY2025) are recurring, suggesting ADNT's adj. EBITDA consistently overstates sustainable earnings power. True "recurring" FCF must deduct a normalized restructuring run-rate of ~$50-100M. Goodwill impairment is properly excluded from adj. EBITDA. [S1]

##### Revenue vs. Adj. EBITDA Trend

| FY | Revenue | Adj. EBITDA | Adj. EBITDA% |
|----|---------|-------------|--------------|
| FY2021 | $14.0B | ~$725M | 5.2% |
| FY2022 | $14.6B | ~$810M | 5.5% |
| FY2023 | $14.5B | ~$845M | 5.8% |
| FY2024 | $14.7B | ~$862M | 5.9% |
| FY2025 | $14.5B | ~$881M | 6.1% |

Gradual margin improvement despite revenue stagnation — driven by EMEA footprint actions and Americas operational improvements. Quality: **MODERATE** — trend is real but heavily depends on adj. EBITDA definition. [S1][S2]

#### 2. Balance Sheet Quality

##### Goodwill & Intangibles

| Item | Value (FQ2 FY2026) | Concern Level |
|------|-------------------|---------------|
| Goodwill | ~$900M (post FY2025 impairment of $333M) | MEDIUM — EMEA impairment risk remains |
| Other intangibles | ~$250M | Low |

FY2025 included a $333M EMEA goodwill impairment — this is important because it signals management (and auditors) formally acknowledged EMEA's structural deterioration. Remaining goodwill is tilted toward Americas (healthier) and prior acquisition premiums. [S1]

**Residual EMEA goodwill impairment risk exists** but the large FY2025 write-down significantly reduced the risk of a repeat.

##### Working Capital
Adient is a JIT supplier with negative-to-neutral working capital dynamics:
- Receivables: typically 30-45 days; collected promptly from creditworthy OEMs
- Inventory: minimal (JIT manufacturing means low inventory buffer)
- Payables: 60-90 days to sub-tier suppliers
- Result: Working capital is NOT a significant cash drain; this is a positive quality attribute.

##### Debt Structure [S1][S3]

| Instrument | Balance (est.) | Rate | Maturity |
|------------|---------------|------|---------|
| Term Loan B | ~$625M | SOFR+175bps (~7.2%) | 2031 |
| Senior Secured Notes | ~$500M | 7.00% | 2028 |
| Senior Unsecured Notes | ~$500M | 7.50% | 2030 |
| Unsecured Notes (legacy) | ~$400M | 4.875% | 2026 (refinanced) |
| ABL Revolver | $0 drawn | SOFR+125bps | 2028 |
| **Total Gross Debt** | **~$2.4B** | | |
| Cash | ~$800M | | |
| **Net Debt** | **~$1.6-1.8B** | | |

Feb 2025 refinancing extended 2026 maturity. However, the new debt carries materially higher coupon (4.875% → 7.50%), creating a significant annual interest cost increase (~$30-40M/year incremental). Net Debt/Adj. EBITDA ~2.0x — manageable but leaves limited room for downward EBITDA revision. [S1][S3]

##### Pension & Employee Obligations
- Defined benefit pension plans primarily in EMEA (Germany, UK)
- Estimated underfunded pension liability: ~$200-400M (underfunded EMEA plans)
- Cash funding requirements ~$30-50M/year
- FLAG: This is an underappreciated liability that reduces true enterprise value. Must be added to net debt in valuation. [S1]

#### 3. Cash Flow Quality

| FY | OCF | CapEx | FCF (S&U def) | FCF Mgmt def |
|----|-----|-------|---------------|--------------|
| FY2021 | $394M | $(284M) | $110M | N/A |
| FY2022 | $374M | $(313M) | $61M | ~$40M |
| FY2023 | $464M | $(299M) | $165M | ~$150M |
| FY2024 | $472M | $(266M) | $206M | ~$180M |
| FY2025 | $546M | $(274M) | $272M | ~$204M |

FCF has improved steadily from post-COVID trough. CapEx as a % of revenue is declining slightly (~2.1% → ~1.9%), which may reflect reduced investment in EMEA as restructuring reduces footprint. Quality: **MODERATE-HIGH** — OCF is real, FCF growing, but management's definition excludes some restructuring cash outflows. [S2]

FY2026 guidance of ~$130M FCF is sharply lower than FY2025's ~$204M due to ~$120-130M restructuring cash payments, not operational deterioration. Normalized post-restructuring FCF should recover to $200-250M+ by FY2027.

#### 4. Earnings Quality Red Flags

| Flag | Severity | Detail |
|------|----------|--------|
| Recurring restructuring charges (adj. out) | MEDIUM | $159M (FY2024), $180M (FY2025); suggestive of structural, not one-time, nature |
| EMEA goodwill impairment | LOW-MEDIUM | $333M write-down taken; residual risk reduced but EMEA remains challenged |
| JV accounting complexity | MEDIUM | YFAS equity-method income can obscure true China cash generation; dividends received ≠ income recognized |
| Interest rate refinancing | MEDIUM | Feb 2025 refi extended maturity but at ~$30-40M higher annual interest cost |
| CEO/CFO both new (Jan 2024) | LOW | New leadership may signal prior management inadequacy; also creates risk of kitchen-sink charges in FY2024-2025 |
| Pension underfunding | LOW | ~$200-400M underfunded EMEA plans are off-balance-sheet economic liability |

#### 5. Adversarial Research Sweep

##### Short Reports / Investigations
**No major published short reports found on ADNT.** The stock has been a long-running value trap by many accounts but has not attracted explicit short-seller reports (unlike, e.g., some Chinese auto companies). The thesis against ADNT is predominantly fundamental (EMEA structural decline, leverage) rather than accounting fraud concerns.

##### Legal / Regulatory Actions [S4]
- **Price-fixing investigations:** Adient's predecessor JCI automotive seating business settled with DOJ on auto parts price-fixing (industry-wide investigation that included multiple Tier 1 suppliers) in the 2014-2018 period. As of FY2025 filings, no material ongoing price-fixing liability.
- **EMEA labor disputes:** Ongoing restructuring in Germany and Czech Republic has led to works council negotiations; management has disclosed ~$120-130M total charge; no criminal allegations.
- **Environmental:** Typical manufacturing liability disclosures; no material ongoing enforcement actions.
- **Derivative suits:** None material in recent proxy disclosures.
- **FLAG:** No smoking gun. ADNT's risks are operational and strategic, not legal/governance. [S1][S4]

##### Competitor/Industry Red Flags
- Industry-wide: automaker warranty claims for seating defects can create recall exposure; Adient has had modest warranty reserve usage but no major recall program
- YFAS JV: Chinese partner (Yanfeng) has independent interests; JV governance is an inherent risk, though the relationship has been stable since JV restructuring in 2020-2021

#### 6. Statement Adjustments for Valuation

To arrive at a "clean" earnings base for valuation:

| Adj. EBITDA (reported) | ~$881M |
|------------------------|--------|
| Less: Normalized restructuring (ongoing) | ~-$75M |
| Less: Pension cash funding | ~-$40M |
| **Adjusted EBITDA (clean)** | **~$766M** |
| Add: D&A | ~$350M |
| Less: CapEx | ~-$274M |
| Less: Interest (cash) | ~-$175M |
| Less: Taxes (normalized) | ~-$75M |
| **Clean FCF (normalized)** | **~$592M Adj EBITDA → ~$170-200M FCF** |

Note: "Normalized" FCF excludes large restructuring payments specific to FY2026 (~$130M guided FCF is depressed by restruc).

#### Source Index

| ID | Source | Description |
|----|--------|-------------|
| S1 | SEC 10-K FY2025 (CIK 1670541) | Income statement, balance sheet, notes, risk factors |
| S2 | ADNT_financials/other/stockanalysis_summary.md | Cash flow, ratios |
| S3 | ADNT_financials/sec_filings/10K_FY2025_summary.md | Debt structure detail |
| S4 | ADNT_financials/other/consensus.md + Tavily search | Litigation, regulatory context |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ADNT/fundamental

## Navigation

- Overview: /stocks/ADNT
- Financials (this page): /stocks/ADNT/financials
- Thesis: /stocks/ADNT/thesis
- Investment Memo: /stocks/ADNT/memo
- Coverage universe: /stocks